Related Experiment Video
Updated: Nov 28, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The effectiveness of early anticoagulant treatment in Covid-19 patients
Yakup Arslan1, Gulden Yilmaz2, Deniz Dogan1
1Department of Pulmonology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey.
Insights
Early anticoagulant treatment with Low Molecular Weight Heparin (LMWH) in hospitalized COVID-19 patients showed improved outcomes. LMWH use was associated with reduced intensive care unit transfers and shorter hospital stays, suggesting clinical benefits.
Area of Science:
- Medical Research
- Infectious Diseases
- Pharmacology
Background:
- COVID-19 is a rapidly spreading infectious disease.
- Thrombosis can worsen COVID-19 outcomes.
- Early intervention is crucial for managing severe infections.
Purpose of the Study:
- To evaluate the impact of early anticoagulant therapy in hospitalized COVID-19 patients.
- To compare outcomes between patients treated with and without Low Molecular Weight Heparin (LMWH).
Main Methods:
- Retrospective comparative cohort study of 413 hospitalized COVID-19 patients.
- Treatment groups: LMWH (n=187) vs. no LMWH (n=226).
- Data collected before and after an updated treatment guide in April 2020.
Main Results:
- LMWH-treated patients had higher d-dimer and platelet counts.
- LMWH-untreated patients showed increased inflammatory markers (ferritin, IL-6, procalcitonin).
- LMWH-treated patients had more comorbidities but fewer ICU transfers and shorter hospital stays.
Conclusions:
- Early anticoagulant treatment with LMWH may enhance clinical outcomes in COVID-19.
- Higher doses of LMWH could potentially shorten hospital stays.
- LMWH treatment appears beneficial for hospitalized COVID-19 patients.
Objectives:
Coronavirus disease 2019 (Covid-19) is an emerging, fast-spreading and worldwide infectious disease that would be deteriorated with the precipitation of systemic or local thrombosis. The aim of current study was evaluating the effects of early anticoagulant treatment in hospitalized Covid-19 patients.
Method:
The present retrospective and comparative cohort study investigated 413 hospitalized Covid-19 patients treated with or without Low Molecular Weight Heparin (LMWH) (n = 187 and 226, respectively) in the Covid Clinics of Gulhane Education and Research Hospital in Ankara, Turkey, between March 18 and May 03, 2020. The treatment groups were consisted of the patients evaluated before and after The Covid-19 Treatment Guide update on April 12, 2020 that included the anticoagulant treatment thereafter.
Results:
The mean age of all 413 patients (204 male and 209 female) at disease onset was 50.6 ± 16.7 years. The LMWH-treated patients had significantly higher coagulation markers such as d-dimer and platelet count than LMWH-untreated patients (p values < 0.05). The inflammatory markers, ferritin, interleukin-6 and procalcitonin were significantly increased in LMWH-untreated patients (p values < 0.05). The presence of any comorbidity was significantly more common in LMWH-treated patients compared to LMWH-untreated group (39.6% vs 19.9%, respectively; p < 0.001). Hypertension and diabetes mellitus were the most frequent comorbidities in both groups. The number of intensive care unit (ICU) transfer and longer length of hospital stay were more commonly observed in LMWH-untreated patients (p values <0.05).
Conclusions:
Early anticoagulant treatment with relatively higher doses of LMWH may improve the clinical outcome of Covid-19 patients and shorten the length of hospital stay.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Endocarditis III: Medical Management

